Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients

被引:102
作者
Wong, KM [1 ]
Shek, CC
Chau, KF
Li, CS
机构
[1] Queen Elizabeth Hosp, Dept Med, Renal Unit, Hong Kong, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
area under the concentration time curve (AUC); tacrolimus (FK); pharmacokinetics; transplant;
D O I
10.1016/S0272-6386(00)70013-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The area under the concentration time curve (AUC) for oral tacrolimus (FK) may provide a more precise model for FK monitoring after renal transplantation. The purpose of this study is to identify a simple, cost-effective method for predicting FK AUG. FK concentrations were measured at 0, 1,2, 4, 6, 8, and 12 hours after the morning dose. The predicted AUCs (AUC(p)s) derived from regression equations were used to estimate the actual 12-hour AUCs (AUC(12)S) The relationship between AUG, and AUC(12) was validated by determining the coefficient of multiple determination (Re), percentage of prediction error (PE%), and percentage of absolute prediction error (APE%). Eighteen stable Oriental renal transplant recipients (9 men, 9 women) with a mean age of 42.6 +/- 6 years and mean body weight of 62.7 +/- 10 kg were recruited for the study. The FK AUC(12) trough, P-hour, and 4-hour concentrations were 125 +/- 24 h ng/mL (range, 87.7 to 181.9 h ng/mL), 6 1: 1.3 ng/mL, 18.1 +/- 4.7 ng/mL, and 11 +/- 2.4 ng/mL, respectively. Trough FK concentration did not have a significant correlation with AUC(12) (r = 0.34; P = 0.17). AUC(p) obtained by a two-time point regression equation using P-hour (C2) and 4-hour (C4) FK concentrations: (AUCp = 16.2 + 2.4(*)C2 +/- 5.9(*)C4) obtained an R-2, PE%, and APE% of 0.93, -0.2X +/- 5.2% (range, -13% to 9.3%), and 3.6% +/- 3.7% (range, 0.02% to 13%), respectively. We conclude that a two-point sampling method using C2 and C4 may be a more cost-effective FK monitoring strategy than morning FK trough levels in transplant recipients. (C) 2000 by the National Kidney Foundation, Inc.
引用
收藏
页码:660 / 666
页数:7
相关论文
共 21 条
[1]   Tacrolimus pharmacokinetics in BMT patients [J].
Boswell, GW ;
Bekersky, I ;
Fay, J ;
Wingard, J ;
Antin, J ;
Weisdorf, D ;
Maher, R ;
Fitzsimmons, W ;
Nash, R .
BONE MARROW TRANSPLANTATION, 1998, 21 (01) :23-28
[2]  
Bowles MJ, 1996, NEPHROL DIAL TRANSPL, V11, P1597
[3]   Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients [J].
Christiaans, M ;
van Duijnhoven, E ;
Beysens, T ;
Undre, N ;
Schäfer, A ;
van Hooff, J .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1271-1273
[4]   Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants [J].
Filler, G ;
Grygas, R ;
Mai, I ;
Stolpe, HJ ;
Greiner, C ;
Bauer, S ;
Ehrich, JHH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1668-1671
[5]   Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy - Technical Note [J].
Gaspari, F ;
Perico, N ;
Signorini, O ;
Caruso, R ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 1998, 54 (06) :2146-2150
[6]   CYCLOSPORINE MONITORING IN RENAL-TRANSPLANTATION - AREA UNDER THE CURVE MONITORING IS SUPERIOR TO TROUGH-LEVEL MONITORING [J].
GREVEL, J ;
WELSH, MS ;
KAHAN, BD .
THERAPEUTIC DRUG MONITORING, 1989, 11 (03) :246-248
[7]   TACROLIMUS, A NEW IMMUNOSUPPRESSANT - A REVIEW OF THE LITERATURE [J].
HOOKS, MA .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (04) :501-511
[8]   Simple bioequivalence criteria: Are they relevant to critical dose drugs? Experience gained from cyclosporine [J].
Johnston, A ;
Keown, PA ;
Holt, DW .
THERAPEUTIC DRUG MONITORING, 1997, 19 (04) :375-381
[9]   PHARMACOKINETICS OF TACROLIMUS IN LIVER-TRANSPLANT PATIENTS [J].
JUSKO, WJ ;
PIEKOSZEWSKI, W ;
KLINTMALM, GB ;
SHAEFER, MS ;
HEBERT, MF ;
PIERGIES, AA ;
LEE, CC ;
SCHECHTER, P ;
MEKKI, QA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :281-290
[10]   CHALLENGES IN CYCLOSPORINE THERAPY - THE ROLE OF THERAPEUTIC MONITORING BY AREA-UNDER-THE-CURVE MONITORING [J].
KAHAN, BD ;
WELSH, M ;
RUTZKY, LP .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :621-624